Shares of Atyr Pharma Inc. (NASDAQ:LIFE) rose 6.8% on Wednesday . The company traded as high as $3.31 and last traded at $3.30, with a volume of 158,901 shares. The stock had previously closed at $3.09.

LIFE has been the subject of a number of research reports. BMO Capital Markets initiated coverage on shares of Atyr Pharma in a research report on Monday, April 11th. They set a “market perform” rating for the company. Zacks Investment Research cut shares of Atyr Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $23.75.

The stock’s 50 day moving average price is $2.87 and its 200 day moving average price is $3.87. The company’s market cap is $78.02 million.

Atyr Pharma (NASDAQ:LIFE) last released its earnings results on Wednesday, May 11th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.02. Equities research analysts forecast that Atyr Pharma Inc. will post ($2.79) earnings per share for the current year.

In related news, insider Grove Matsuoka bought 12,412 shares of the business’s stock in a transaction on Wednesday, May 11th. The stock was bought at an average price of $3.04 per share, for a total transaction of $37,732.48. Following the transaction, the insider now directly owns 2,412 shares in the company, valued at $7,332.48. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

An institutional investor recently raised its position in Atyr Pharma stock. RS Investment Management Co. LLC raised its position in shares of Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned 5.10% of Atyr Pharma worth $11,857,000 at the end of the most recent quarter.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.